XBiotech (NASDAQ:XBIT – Get Free Report) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.21), FiscalAI reports.
XBiotech Trading Down 0.2%
Shares of XBIT stock opened at $2.50 on Friday. The firm’s fifty day moving average price is $2.40 and its two-hundred day moving average price is $2.43. The firm has a market capitalization of $76.07 million, a P/E ratio of -1.66 and a beta of 0.88. XBiotech has a 1 year low of $2.09 and a 1 year high of $3.61.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the company. XTX Topco Ltd raised its position in shares of XBiotech by 44.1% in the 4th quarter. XTX Topco Ltd now owns 21,703 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 6,647 shares in the last quarter. Bridgeway Capital Management LLC raised its holdings in XBiotech by 50.4% in the 4th quarter. Bridgeway Capital Management LLC now owns 89,547 shares of the biopharmaceutical company’s stock valued at $214,000 after buying an additional 30,000 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in XBiotech in the fourth quarter valued at $32,000. State Street Corp lifted its stake in shares of XBiotech by 8.5% in the fourth quarter. State Street Corp now owns 73,006 shares of the biopharmaceutical company’s stock worth $174,000 after acquiring an additional 5,700 shares during the period. Finally, Jane Street Group LLC boosted its stake in shares of XBiotech by 25.1% in the 4th quarter. Jane Street Group LLC now owns 69,738 shares of the biopharmaceutical company’s stock valued at $167,000 after purchasing an additional 13,971 shares during the last quarter. Institutional investors own 55.70% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Report on XBiotech
XBiotech Company Profile
XBiotech Inc is a clinical-stage biopharmaceutical company developing human antibodies to treat cancer and other inflammatory-driven diseases. The company’s core technology, the True Human™ antibody platform, enables the discovery and development of monoclonal antibodies that mimic the human immune response without the need for genetic humanization. XBiotech’s lead therapeutic candidate targets interleukin-1 alpha (IL-1α), a key mediator of inflammation associated with tumor growth and chronic disease.
The company’s most advanced program, Xilonix® (MABp1), is a first-in-class anti-IL-1α antibody that has completed Phase 3 clinical trials in metastatic colorectal cancer patients.
Featured Stories
- Five stocks we like better than XBiotech
- McDonald’s Is the Cheapest It’s Been in Years—Does That Make It a Buy?
- Karman: Defense Darling’s Outlook Strengthens After 40% Drop
- Aeluma’s Post-Earnings Dip Creates a Buying Opportunity
- Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.
